KR20150128858A - 항-il-23 항체를 사용한 건선의 치료 방법 - Google Patents

항-il-23 항체를 사용한 건선의 치료 방법 Download PDF

Info

Publication number
KR20150128858A
KR20150128858A KR1020157027833A KR20157027833A KR20150128858A KR 20150128858 A KR20150128858 A KR 20150128858A KR 1020157027833 A KR1020157027833 A KR 1020157027833A KR 20157027833 A KR20157027833 A KR 20157027833A KR 20150128858 A KR20150128858 A KR 20150128858A
Authority
KR
South Korea
Prior art keywords
antibody
amg
months
amount
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157027833A
Other languages
English (en)
Korean (ko)
Inventor
존 피. 깁스
웨인 추지
웨이-지안 팬
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150128858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20150128858A publication Critical patent/KR20150128858A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
KR1020157027833A 2013-03-15 2014-02-25 항-il-23 항체를 사용한 건선의 치료 방법 Ceased KR20150128858A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
US61/789,777 2013-03-15
PCT/US2014/018293 WO2014149425A1 (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Publications (1)

Publication Number Publication Date
KR20150128858A true KR20150128858A (ko) 2015-11-18

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027833A Ceased KR20150128858A (ko) 2013-03-15 2014-02-25 항-il-23 항체를 사용한 건선의 치료 방법

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP2968488A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
CN107206081A (zh) * 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
AU2017241776B2 (en) * 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
EP3560956A3 (en) * 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
WO2020016838A2 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
MX2021005236A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
MX2021011328A (es) * 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2426145B1 (en) * 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
WO2010002776A2 (en) 2008-06-30 2010-01-07 Black & Decker Inc. Cord protector for power tools
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23

Also Published As

Publication number Publication date
JP2016517408A (ja) 2016-06-16
JP2021102644A (ja) 2021-07-15
US20200277368A1 (en) 2020-09-03
AU2019200206A1 (en) 2019-01-31
EP3689369A1 (en) 2020-08-05
US20220135668A1 (en) 2022-05-05
HK1219425A1 (zh) 2017-04-07
US20160060337A1 (en) 2016-03-03
CR20150572A (es) 2016-04-25
SG11201507482UA (en) 2015-10-29
AU2020270495A1 (en) 2020-12-17
PH12019502700A1 (en) 2020-12-07
CA2906382A1 (en) 2014-09-25
WO2014149425A1 (en) 2014-09-25
CL2015002723A1 (es) 2016-03-28
IL241342A0 (en) 2015-11-30
TN2015000403A1 (en) 2017-01-03
CN105209064A (zh) 2015-12-30
IL275093A (en) 2020-07-30
AP2015008803A0 (en) 2015-10-31
SG10201804954UA (en) 2018-07-30
PH12015502129A1 (en) 2016-01-25
JP2023011815A (ja) 2023-01-24
EA201591581A1 (ru) 2016-01-29
AU2014238148A1 (en) 2015-10-08
JP2020063237A (ja) 2020-04-23
EP2968488A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US20220135668A1 (en) Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
US20200283517A1 (en) Methods for treating chron's disease using an anti-il23 antibody
EP3757126B1 (en) Methods of treating psoriatic arthritis using il-17 antagonists
KR20200015477A (ko) 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체
RU2714919C2 (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
KR20210032441A (ko) 브라지쿠맙을 이용한 궤양성 대장염의 치료
KR20250044344A (ko) 아토피 피부염의 치료에 유용한 il-15 저해제
HK40034615A (en) Methods for treating psoriasis using an anti-il-23 antibody
AU2018263159A1 (en) Methods of selectively treating asthma using IL-17 antagonists
HK40034614A (en) Methods for treating crohn’s disease using an anti-il23 antibody
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190225

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200825

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210623

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200825

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I